49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

4 trials found

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-001508-12-FR (EUCTR)	05/02/2019	13/11/2018	Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SL ...	A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess p ...	Systemic lupus erythematosus (SLE) MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: ...	Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY736 Product Code: CFZ533 ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Taiwan;Spain;Thailand;Russian Federation;Israel;France;Czech Republic;Hungary;Argentina;Poland;Austr ...
2	EUCTR2018-001508-12-ES (EUCTR)	12/12/2018	09/10/2018	Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SL ...	A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess p ...	Systemic lupus erythematosus (SLE) MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: ...	Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY736 Product Code: CFZ533 ...	Novartis Farmacéutica, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Taiwan;Spain;Thailand;Russian Federation;Israel;France;Czech Republic;Hungary;Argentina;Poland;Austr ...
3	EUCTR2018-001508-12-DE (EUCTR)	05/12/2018	28/08/2018	Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SL ...	A placebo-controlled, patient and investigator blinded, randomized parallelcohort study to assess ph ...	Systemic lupus erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: ...	Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY736 Product Code: CFZ533 ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	135	Phase 2	United States;Czechia;Taiwan;Spain;Thailand;Israel;Russian Federation;France;Czech Republic;Hungary; ...
4	EUCTR2018-001508-12-CZ (EUCTR)	02/11/2018	28/08/2018	Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SL ...	A placebo-controlled, patient and investigator blinded, randomized parallelcohort study to assess ph ...	Systemic lupus erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: ...	Product Code: VAY736 INN or Proposed INN: ianalumab Other descriptive name: VAY736 Product Code: CFZ533 ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	135	Phase 2	Argentina;Russian Federation;Hungary;Japan;Thailand;Spain;Czech Republic;China;Taiwan;Korea, Republi ...

First Previous1Next Last